Search
Now showing items 1-10 of 34
Monoamine oxidase inhibition by novel quinolinones
(2014)
Parkinson’s disease (PD) is an age-related neurodegenerative disorder. The degeneration of the neurons of the substantia nigra in the midbrain leads to the loss of dopamine from the striatum, which
is responsible for the ...
Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase
(2014)
BACKGROUND AND RATIONALE
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder affecting the central nervous system, primarily, the substantia nigra. It is characterized by loss of dopaminergic ...
The monoamine oxidase inhibition properties of caffeine analogues containing saturated C–8 substituents
(North-West University, 2010)
Parkinson’s disease (PD) is a progressive neurodegenerative disorder, characterized
pathologically by a marked loss of dopaminergic nigrostriatal neurons and clinically by disabling movement disorders. PD can be treated ...
The synthesis and evaluation of 8–benzyloxycaffeine analogues as inhibitors of monoamine oxidase B
(North-West University, 2009)
Monoamine oxidase, especially monoamine oxidase 8 (MAO-B), plays a major role in the therapy of Parkinson's disease (PO). MAO-8 is the main enzyme responsible for the catabolism of dopamine in the substantia nigra of the ...
Monoamine oxidase inhibition by indanone and benzoquinone analogues
(North-West University (South Africa) , Potchefstroom Campus, 2015)
Parkinson’s disease (PD) is a neurological disorder of which aging is the greatest risk factor. Over the next fifteen years, the number of persons affected by PD worldwide is expected to increase from 4.6 million to 9.3 ...
The synthesis and evaluation of (E)-styrylisatin analogues as inhibitors of monoamine oxidase B
(North-West University, 2008)
Monoamine oxidase B (MAO-B) inhibitors are currently clinically used in the symptomatic
treatment of Parkinson's disease (PO) and may also possess .neuroprotective activity. The
irreversible MAO-'B inhibitor, (R)-deprenyl, ...
Identification of monoamine oxidase inhibitors using a molecular modelling approach
(2014)
Monoamine oxidase (MAO) is an enzyme located on the outer mitochondrial membrane and is considered to be a target for the treatment of diseases such as Parkinson’s disease and depression. MAO may be classified into two ...
Monoamine oxidase inhibitory activities of heterocyclic chalcones
(2013)
Parkinson’s disease is the second most common age-related neurodegenerative disease after Alzheimer’s disease. The characteristic pathological feature of Parkinson’s disease is the loss of neurons in the substantia nigra ...
Synthesis and biological evaluation of 6-substituted coumaranone derivatives and related compounds as monoamine oxidase inhibitors
(2014)
Parkinson’s disease (PD) is an age related neurodegenerative disorder that presents with both motor and non-motor symptoms. The most common pathological characteristic of PD is the loss of the pigmented dopaminergic neurons ...
The design, synthesis and evaluation of aminocaffeine derivatives as inhibitors of monoamine oxidase B
(North-West University, 2011)
Monoamine oxidase (MAO) is responsible for dopamine catabolism in the brain and therefore is especially important in the treatment of Parkinson's disease (PD). MAO–B inhibition provides symptomatic relief by indirectly ...